A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer
- 1 August 1985
- Vol. 56 (3) , 457-460
- https://doi.org/10.1002/1097-0142(19850801)56:3<457::aid-cncr2820560307>3.0.co;2-7
Abstract
Twenty-five patients with metastatic prostate cancer resistant to primary hormone therapy, received high-dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES-P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high-dose Stilphostrol in the treatment of hormone-resistant prostate cancer is limited.This publication has 9 references indexed in Scilit:
- Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancerThe American Journal of Medicine, 1984
- Chemohormonal therapy of metastatic prostate cancer. A pilot studyCancer, 1983
- Systemic Treatment of Advanced Prostatic Cancer: Development of a New System for Defining ResponseJournal of Urology, 1981
- The Chemotherapy of Prostatic AdenocarcinomaAnnals of Internal Medicine, 1980
- Diethylstilbestrol: Recommended Dosages for Different Categories of Breast Cancer PatientsJAMA, 1977
- Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer GroupJAMA, 1977
- Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphateUrology, 1976
- Paraplegia and paraparesis due to prostatic cancer: Use of intravenous diethylstilbestrol diphosphateUrology, 1974